MARKET

ANAB

ANAB

AnaptysBio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.72
-0.35
-1.59%
Closed 16:43 04/16 EDT
OPEN
21.94
PREV CLOSE
22.07
HIGH
21.94
LOW
20.80
VOLUME
258.12K
TURNOVER
--
52 WEEK HIGH
35.85
52 WEEK LOW
13.92
MARKET CAP
594.40M
P/E (TTM)
-29.6397
1D
5D
1M
3M
1Y
5Y
8-K: ANAPTYSBIO, INC
Edgar Online - (EDK = 8-Ks/S1/S-4) · 6d ago
BRIEF-AnaptysBio Announces Appointment Of Oleg Nodelman To Board Of Directors
reuters.com · 6d ago
Press Release: AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors
Dow Jones · 6d ago
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher
Celebrations may be in order for AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders, with the analysts delivering a...
Simply Wall St. · 03/18 05:32
Why AnaptysBio Stock Is Attractive After 30% Selloff
Benzinga · 03/16 20:06
AnaptysBio is set for a catalyst-rich phase after the recent selloff: Truist
Truist Securities has upgraded AnaptysBio ([[ANAB]] +6.1%) to buy from hold citing the recent selloff following the company’s failure of the mid-stage trial for Imsidolimab in moderate-to-severe palmoplantar pustulosis.Upped by
Seekingalpha · 03/16 18:16
DJ AnaptysBio Shares Rise on Truist Upgrade After Last Week's Plunge >ANAB
Dow Jones · 03/16 15:41
DJ AnaptysBio Price Target Raised to $34.00/Share From $27.00 by Truist Securities
Dow Jones · 03/16 11:34
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANAB. Analyze the recent business situations of AnaptysBio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANAB stock price target is 28.50 with a high estimate of 42.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 215
Institutional Holdings: 43.23M
% Owned: 157.96%
Shares Outstanding: 27.37M
TypeInstitutionsShares
Increased
35
861.66K
New
23
3.16M
Decreased
45
3.10M
Sold Out
18
2.07M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Independent Director
James Topper
President/Chief Executive Officer/Director
Hamza Suria
Chief Financial Officer
Dennis Mulroy
Chief Operating Officer/General Counsel
Eric Loumeau
Other
Paul Lizzul
Lead Director/Independent Director
Hollings Renton
Director
Magda Marquet
Director
Oleg Nodelman
Independent Director
Dennis Fenton
Independent Director
J. Ware
Independent Director
Laura Hamill
Independent Director
John Schmid
Independent Director
J. Anthony Ware
No Data
  • All
  • Financials
  • Insiders
More
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).

Webull offers kinds of AnaptysBio Inc stock information, including NASDAQ:ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.